Longeveron Inc at SRAX Sequire Biotechnology Conference (Virtual) Transcript
Hi, my name is Chris Min, and I am the Chief Medical Officer and Interim CEO of Longeveron, and I'm happy to be presenting today to the Sequire Technology Conference.
Longeveron is a regenerative medicine company. I have a disclaimer slide, but as always, the key thing is that forward-looking statements contained in this presentation are made as of the date of this presentation and the company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
With that disclaimer out of the way, I'd like to discuss our mission, which is to deliver regenerative medical therapies for unmet medical needs. Our product is Lomecel-B, which is a pipeline of product. Lomecel-B is derived from allogeneic medicinal signaling cells isolated from the bone marrow of healthy young adults. We have three clinical-stage programs: hypoplastic left heart syndrome; aging-related frailty; and Alzheimer's disease.
This is the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |